HOT NEWS
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product sup... » Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides ...
43 research talents awarded scholarships to help secure Denmark's future » 43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will toda...
Novartis drug Signifor® recommended by CHMP for EU approval » The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ado...
Genzyme Announces European Approval of Framingham Manufacturing Plant » Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Me...
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe » AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provi...
MyAsthma App - a New Dimension in Asthma Control » GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health...
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted ... » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced...
Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Sec... » Bayer HealthCare has submitted an application for marketing authorization to the European Medicines ...
Avastin receives EU approval for the treatment of women with newly diagnosed, ad... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Avastin (beva...
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy » Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in...
Abbott
AbbottAbbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. For more information, please visit http://www.abbott.com

Abbott RSS Channel
Title Filter     Display # 
# Article Title Hits
1 First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy 1933
2 EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets 6793
3 Abbott Announces European Launch of TREK(TM) Catheter System 8055
4 Abbott Honored as a Great Place to Work Across Europe 7800
5 Abbott Completes Acquisition of Solvay Pharmaceuticals 8974
6 Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline 9125
7 Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes 8860
8 Abbott to Acquire Solvay Pharmaceuticals Business 8709
9 Abbott to Acquire Visiogen, Expanding Vision Care Portfolio 7989
10 Abbott Reports Strong Second Quarter Results 7706
11 Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent 7448
12 Abbott's XIENCE V(R) Demonstrates Impressive Results in SPIRIT V Study 3671
13 New data to be presented on Abbott's market-leading XIENCE V(R) stent 2092
14 Abbott Reports 16 Percent Earnings Growth in First Quarter 1724
15 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium 3516
16 The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent 2148
17 Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics 1788
18 Abbott Receives EC Clearance on Acquisition of Advanced Medical Optics 1899
19 Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter 1851
20 Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection 2196
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2
Bookmark and Share